Prespecified Third Interim Analysis of the DARolutamide ObservationaL (DAROL) Study

Nov 3

Written By Kristofer Prepelica, PhD

Kristofer Prepelica, PhD

The PCCTC’s Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate (TALENT) Activated